Loading
KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming subunit of the voltage-gated potassium (Kv) channel involved in the regulation of cardiomyocyte excitability and important in normal development and functions of myocardium, inner ear, stomach and colon. Associates with KCNE beta subunits that modulates current kinetics. Induces a voltage-dependent current by rapidly activating and slowly deactivating potassium-selective outward current.
Open Targets scores its association with cancer at 0.59 (direct and indirect evidence; datatypes literature 0.92, animal model 0.45, genetic association 0.61, clinical 0.76).
In plain words · KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming subunit of the voltage-gated potassium (Kv) channel involved in the regulation of cardiomyocyte excitability and important in normal development and functions of myocardium, inner ear, stomach and colon.
No product in this corpus aims at KCNQ1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCNQ1: RNA tissue enhanced (adrenal gland 196 nTPM, stomach 1 96 nTPM); high antibody staining in 6 normal tissues; highest cancer staining colorectal cancer (1 of 10 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 2 specific cancer types at or above 0.5 (Lambert-Eaton myasthenic syndrome, Beckwith-Wiedemann syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas KCNQ1 tissue; Open Targets ENSG00000053918 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Sanguinetti M.C. et al, Nature, 1996, "Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel". Source.
Sources: HGNC HGNC:6294 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P51787 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000053918 (association with cancer (MONDO_0004992) 0.59; (GraphQL API, CC0))
Pore-forming subunit of the voltage-gated potassium (Kv) channel involved in the regulation of cardiomyocyte excitability and important in normal development and functions of myocardium, inner ear, stomach and colon. Associates with KCNE beta subunits that modulates current kinetics. Induces a voltage-dependent current by rapidly activating and slowly deactivating potassium-selective outward current. Also promotes a delayed voltage activated potassium current showing outward rectification characteristic. During beta-adrenergic receptor stimulation, participates in cardiac repolarisation by associating with KCNE1 to form the I(Ks) cardiac potassium current that increases the amplitude and slows down the activation kinetics of outward potassium current I(Ks). Muscarinic agonist oxotremorine-M strongly suppresses KCNQ1/KCNE1 current. Location: Cell membrane; Cytoplasmic vesicle membrane; Early endosome; Membrane raft (UniProt). Locus 11p15.5-p15.4 (HGNC).
RNA: tissue enhanced (adrenal gland 196 nTPM, stomach 1 96 nTPM), detected in many normal tissues.
Medium: Appendix, Bone marrow, Breast, Bronchus, Cerebellum, Cervix, Colon, Epididymis.
RNA cancer enhanced: Kidney Chromophobe 120 pTPM.
Medium only: breast cancer, carcinoid, cervical cancer, liver cancer.
HPA KCNQ1 tissue · HPA KCNQ1 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KCNQ1" OR ABSTRACT:"KCNQ1" OR TITLE:"potassium voltage-gated channel subfamily Q member 1" OR ABSTRACT:"potassium voltage-gated channel subfamily Q member 1" OR TITLE:"Potassium voltage-gated channel subfamily KQT member 1" OR ABSTRACT:"Potassium voltage-gated channel subfamily KQT member 1" OR TITLE:"Kv7.1" OR ABSTRACT:"Kv7.1" OR TITLE:"KCNA8" OR ABSTRACT:"KCNA8" OR TITLE:"KVLQT1" OR ABSTRACT:"KVLQT1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCNQ1, not a curated reading list.